InfectoGnostics

Breaking New Ground in Diagnostics of Infections

As a public-private partnership, the InfectoGnostics Research Campus Jena is breaking new ground in the diagnosis of infections. More than 30 partners from science, medicine and industry are working together to develop innovative solutions for the rapid and cost-effective on-site diagnosis of infectious diseases. As an Thuringian innovation cluster, InfectoGnostics is deeply rooted in Thuringia's innovation landscape and is also well connected with other clusters, commercial enterprises, research institutions, clinics and other stakeholders both nationally and internationally.

Read more our mission and the concept of our campus.

News

Find out more about current advancements in diagnostics and infection research in our most recent news or browse through our news archive.

Strategy meeting of the Council of the German BioRegions

Analysis and strategic realignment at the meeting in Cologne

Read more

Consistently positive response at the joint Thuringian diagnostics stand at MEDICA 2023

The two Thuringian innovation clusters Medways and InfectoGnostics organized a joint stand for the first time in the Diagnostics Hall 3

Read more
Austausch zwischen LifeScience-Experten aus Norditalien mit der Landesentwicklungsgesellschaft Thüringen und dem Forschungscampus InfectoGnostics in Modena und Mailand.

Thuringia's life sciences sector intensifies international cooperation in northern Italy

From October 2 to 5, 2023, the State Development Agency of Thuringia (LEG) together with the InfectoGnostics Research Campus presented the Thuringian life sciences sector during a trip to Italy. The trip was supported by Germany Trade and Invest (GTAI) and organized by the Italian Chamber of Commerce in Germany in cooperation with LEG and took the…

Read more
[Translate to English:] Das Gyntect-Testkit der Firma oncgnostics: Mit dem epigenetischen Test lassen sich Krebsvorstufen früh erkennen.

Hong-Kong Firm invests in Jena-Based Ongnostics GmbH

The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a multi-million Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics – an InfectoGnostics partner – has developed the cancer diagnostic Gyntect for the reliable detection of cervical cancer. The goal now is to expand the distribution of tests developed by…

Read more

Events

Here you will find the current events in our network as well as an overview of previous events that have already taken place.

No news available.

Projects

  • ADA

    Adaptable decentralised diagnostics for veterinary and human medicine

    In the "ADA" project, a cost-effective, open test platform for screening for Staphylococcus aureus / MRSA in human and veterinary medicine is being developed.

    Find out more about ADA.

  • InfectoXplore

    Spektroskopische Plattform zur Diagnostik von Infektionen aus Blut

    Mit „InfectoXplore“ wird am InfectoGnostics Forschungscampus eine Diagnostik-Plattform aufgebaut, mit der erstmals auch aus Blutkulturen eine umfassende Raman-spektroskopische Erreger-Analyse durchgeführt werden kann.

    Find out more about InfectoXplore.

  • Resistovac

    Testformate zur schnellen Erfassung des Impfstatus

    Im Projekt „RESISTOVAC“ werden verschiedene Testformate entwickelt, die zur schnellen Erfassung des Impfstatus von Menschen und Tieren eingesetzt werden können und so entscheidend zur Prävention von Infektionskrankheiten weltweit beitragen sollen.

    Find out more about Resistovac.

  • Preplex

    Maschinelles Lernen zur Identifikation molekularer Muster

    Durch maschinelles Lernen sollen im Projekt „PREPLEX“ molekulare Muster identifiziert werden, die einen Hinweis darauf geben, wie Bakterien die Wirkmechanismen von Antibiotika außer Kraft setzen.

    Find out more about Preplex.

  • POCT-ambulant

    Forschungs-Entwicklungs-Praxis-Dialog zur bedarfsgerechten Entwicklung von PoC-Tests

    Mit „POCT-ambulant“ entwickelt der Forschungscampus ein strukturiertes und systematisches Programm zur Beurteilung des Patientennutzens und des klinischen Bedarfes von Vor-Ort-Testverfahren (sogenannten Point-of-Care-Verfahren) im niedergelassenen Bereich.

    Find out more about POCT-ambulant.

  • Screenshot of video

    FastAlert

    Früherkennung von Erregern und Resistenzen in Abwasser

    In „FastAlert“ soll ein Analysesystem zur prozessnahen Erregerdetektion in Abwasseranlagen entstehen, um Infektionserreger und Resistenzgene zu überwachen.

    Find out more about FastAlert.

Partners

Under the maxim "diagnostics before therapy", we successfully realise projects as a public-private partnerships (PPP) with strong partners from industry and science. On the page "partners" you will find an overview of all our campus members.  Here you can first get to know a random selection of our partners: